Recombinant Human Insulin Production in Escherichia coli: Biotechnological Advances and Therapeutic Implications

This manuscript presents a biotechnology-based conceptual analysis of recombinant human insulin production in Escherichia coli and advances a theoretical framework for molecular therapeutic personalization in diabetes mellitus. While recombinant insulin remains a cornerstone of diabetes management, current formulations are largely standardized and do not fully account for inter-individual genetic and metabolic variability. The work integrates fundamental principles of recombinant DNA technology, bacterial expression systems, protein folding and purification processes, and biological determinants of insulin response. From this interdisciplinary perspective, the study explores the theoretical feasibility of engineering insulin variants with differentiated pharmacological properties tailored to specific metabolic profiles. Technical, ethical, and regulatory constraints are critically examined, emphasizing that the proposal remains conceptual and unvalidated experimentally. Nonetheless, the manuscript contributes to the broader discourse on precision medicine by positioning recombinant biotechnology not only as a production platform but as a rational molecular design tool for future personalized therapies in diabetes mellitus. Keywords: recombinant insulin, Escherichia coli, diabetes mellitus, protein engineering, therapeutic personalization, metabolic variability, precision medicine.